Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.


TSXV:ARCH - Post by User

Post by Viking2233on Jul 05, 2023 1:53pm
115 Views
Post# 35527661

Interesting day of trading

Interesting day of tradingSo we open up at $2.05 and CIBC quicklyknocks it down to $2 but suddenly Anonymous shows up on scene and starts buying aggressively here driving us up to $2.14, thats a big swing. CIBC is hanging inbthere firing bullets on the sell side. We have a Mexican stand off here. I cant see the  shorts winning in the long run. The science is just too good, risk of side effects dimished, in fact higher doses are tolerated in humans with successful higher dose study which in fact should improve results. No threat of dilution as we have $5M from Canadian government and recent FDA phase 2 clinical trial for AKI. The stars are aligning here and you cant keep a good horse down. This should be trading at $15 today so $2.14 is a screaming buy. This will be a $75 a - $100 stock in tge future. We have zero competition in our field. I think big pharma has us on their radar screen with bags of cash to spend!!
<< Previous
Bullboard Posts
Next >>